ChemoCentryx licenses investigational drug for rheumatoid arthritis to GlaxoSmithKline
Under the terms of the transaction, ChemoCentryx will receive an option exercise fee of USD 25 million and will be eligible for further milestone payments and royalties. GSK will be solely responsible for funding the further clinical development and commercialization of CCX354 worldwide.
HBM BioVentures has invested USD 13.7 million in ChemoCentryx and is with an ownership stake of 8% one of the company’s largest shareholders. The book value of the investment is USD 18.5 million and will not be changed in accordance with HBM BioVentures’ valuation principles, in spite of this positive news.
CCX354 is already the second drug candidate from ChemoCentryx licensed to GSK. In January 2010, the two companies closed a similar transaction for CCX282-B, an investigational drug for the treatment of inflammatory bowel diseases such as Crohn’s disease. ChemoCentryx has a number of additional products in development, including three further drugs in clinical development.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.